In fact, obesity is often associated with foot pain, as well as many other health concerns
Even more encouraging, a recent case-control study found reduced alcohol consumption in obese patients receiving tirzepatide (63), providing additional support for potential therapeutic applications
Major differences were observed at the level of dominant families: Clostridiaceae, Bacteroidaceae, Porphyromonadaceae, Rikenellaceae, Deferribacteraceae, Lactobacillaceae, and Helicobacteraceae increased by 12.27-fold ( p = 0.0429), 2.17-fold ( p = 0.0357), 0.25-fold, 1.65-fold, 6.86-fold, 0.26-fold and 7.43-fold, respectively, vs HF diabetic control, and Erysipelotrichaceae decreased from 42.03% in HF diabetic control to 8.15% in CB0313.1-treated mice
UK prescribers working with existing GLP-1 and dual agonist therapies generally advise patients to: Choose a consistent day of the week for injection and set a reminder Document the time and site of each injection in a diary or app Report any unexpected or worsening symptoms promptly to their GP, specialist, or trial team Not adjust the dose independently dose escalation should always be supervised If you are considering joining a clinical trial involving retatrutide, NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) is the current UK service for identifying registered clinical studies and is the recommended starting point for patients
